File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Epidemiology and outcome of post-transplant lymphoproliferative disorders in pediatric liver transplant receipient

TitleEpidemiology and outcome of post-transplant lymphoproliferative disorders in pediatric liver transplant receipient
Other TitlesEpidemiology & outcome of post-transplant lymphoproliferative disorders in pediatric liver transplant receipient
Authors
Issue Date2015
PublisherBlackwell Publishing Ltd.
Citation
The 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Varese, Italy, 22-24 October 2015. In British Journal of Haematology Supplement, 2015, v. 171 suppl. 1, p. 72-73, abstract no. 146 How to Cite?
AbstractBACKGROUND/OBJECTIVES: Post-transplant lymphoproliferative disorder (PTLD) has a higher incidence in children than adults due to high rate of Epstein-Barr virus seronegativity. We reviewed the epidemiology and outcome of PTLD diagnosed in pediatric liver transplant recipients. DESIGN/METHODS: To determine the cumulative incidence and review the clinical data of PTLD diagnosed in the cohort of pediatric patients (<18 years) who had liver transplantation performed between 1 January 2001 and 31 December 2012 in the major liver transplantation centre (Queen Mary Hospital) of Hong Kong. RESULTS: Among 75 cases of pediatric liver transplantation performed during the study period, 17 cases of PTLD (seven males) were diagnosed, giving cumulative incidence of 6.8% at 1 year and 22% at 5 years. Median ages of liver transplantation and diagnosis of PTLD were 9.5 months (range: 6–51 months) and 31.2 months (range: 10–114 months), respectively. Median duration from time of transplantation to diagnosis of PTLD was 18.4 months (range: 4.1–65 months). The series consisted of 10 infectious mononucleosis-like cases, 2 polymorphic, 4 monomorphic (3 Burkitt, 1 DLBCL) and 1 T cell PTLDs. One fulminant case (polymorphic PTLD, leukemic presentation) died prior to any treatment. The rest had reduction/cessation of immunosuppressive drugs. Three cases went into CR. Nine cases received rituximab only; eight went into CR. One case required a second course of rituximab for relapsed disease. Five cases received chemotherapy _ rituximab. Two cases entered CR and one case required further chemotherapy for relapsed disease. The case of T cell PTLD was salvaged by allogeneic stem cell transplantation. CONCLUSION: This series demonstrated the high incidence of PTLD in the young liver transplant recipients, supporting the need of regular clinical and viral surveillance for early detection. Most cases respond to reduction of immunosuppressive drug or specific treatment.
DescriptionThis free journal suppl. entitled: Special Issue: Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma Abstracts ... 2015
Persistent Identifierhttp://hdl.handle.net/10722/234223
ISSN

 

DC FieldValueLanguage
dc.contributor.authorChiang, AKS-
dc.contributor.authorHuang, S-
dc.contributor.authorChung, BHY-
dc.contributor.authorCheuk, DKL-
dc.contributor.authorHa, SY-
dc.contributor.authorChan, GCF-
dc.date.accessioned2016-10-14T06:59:56Z-
dc.date.available2016-10-14T06:59:56Z-
dc.date.issued2015-
dc.identifier.citationThe 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Varese, Italy, 22-24 October 2015. In British Journal of Haematology Supplement, 2015, v. 171 suppl. 1, p. 72-73, abstract no. 146-
dc.identifier.issn0963-1860-
dc.identifier.urihttp://hdl.handle.net/10722/234223-
dc.descriptionThis free journal suppl. entitled: Special Issue: Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma Abstracts ... 2015-
dc.description.abstractBACKGROUND/OBJECTIVES: Post-transplant lymphoproliferative disorder (PTLD) has a higher incidence in children than adults due to high rate of Epstein-Barr virus seronegativity. We reviewed the epidemiology and outcome of PTLD diagnosed in pediatric liver transplant recipients. DESIGN/METHODS: To determine the cumulative incidence and review the clinical data of PTLD diagnosed in the cohort of pediatric patients (<18 years) who had liver transplantation performed between 1 January 2001 and 31 December 2012 in the major liver transplantation centre (Queen Mary Hospital) of Hong Kong. RESULTS: Among 75 cases of pediatric liver transplantation performed during the study period, 17 cases of PTLD (seven males) were diagnosed, giving cumulative incidence of 6.8% at 1 year and 22% at 5 years. Median ages of liver transplantation and diagnosis of PTLD were 9.5 months (range: 6–51 months) and 31.2 months (range: 10–114 months), respectively. Median duration from time of transplantation to diagnosis of PTLD was 18.4 months (range: 4.1–65 months). The series consisted of 10 infectious mononucleosis-like cases, 2 polymorphic, 4 monomorphic (3 Burkitt, 1 DLBCL) and 1 T cell PTLDs. One fulminant case (polymorphic PTLD, leukemic presentation) died prior to any treatment. The rest had reduction/cessation of immunosuppressive drugs. Three cases went into CR. Nine cases received rituximab only; eight went into CR. One case required a second course of rituximab for relapsed disease. Five cases received chemotherapy _ rituximab. Two cases entered CR and one case required further chemotherapy for relapsed disease. The case of T cell PTLD was salvaged by allogeneic stem cell transplantation. CONCLUSION: This series demonstrated the high incidence of PTLD in the young liver transplant recipients, supporting the need of regular clinical and viral surveillance for early detection. Most cases respond to reduction of immunosuppressive drug or specific treatment.-
dc.languageeng-
dc.publisherBlackwell Publishing Ltd.-
dc.relation.ispartofBritish Journal of Haematology Supplement-
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.titleEpidemiology and outcome of post-transplant lymphoproliferative disorders in pediatric liver transplant receipient-
dc.title.alternativeEpidemiology & outcome of post-transplant lymphoproliferative disorders in pediatric liver transplant receipient-
dc.typeConference_Paper-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.emailChung, BHY: bhychung@hku.hk-
dc.identifier.emailCheuk, DKL: cheukkld@hku.hk-
dc.identifier.emailHa, SY: syha@hku.hk-
dc.identifier.emailChan, GCF: gcfchan@hku.hk-
dc.identifier.authorityChiang, AKS=rp00403-
dc.identifier.authorityChung, BHY=rp00473-
dc.identifier.authorityChan, GCF=rp00431-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/bjh.13753-
dc.identifier.pmid26434375-
dc.identifier.hkuros267617-
dc.identifier.volume171-
dc.identifier.issuesuppl. 1-
dc.identifier.spage72, abstract no. 146-
dc.identifier.epage73, abstract no. 146-
dc.publisher.placeUnited Kingdom-
dc.customcontrol.immutablesml 161123-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats